Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midostaurin in Core-binding Factor Acute Myeloid Leukemia
NCT03686345Phase 2Terminated
- Sponsor
- ASST Grande Ospedale Metropolitano Niguarda
- Start
- Jul 2018
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of midostaurin in acute myeloid leukemia (AML), sponsored by ASST Grande Ospedale Metropolitano Niguarda. Primary endpoint: Relapse Incidence at 2 years. Started Jul 2018; status: terminated.
02
Drugs
midostaurin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03686345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03686345.